Latest News

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

CROI 2026 showcased breakthroughs alongside funding crisis disrupting global and domestic HIV services.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

Federal policy changes including Medicaid work requirements and ADAP eligibility restrictions threaten access to HIV medications.

Historical redlining policies correlate with current geographic disparities in HIV treatment access and care quality.

Long-acting injectable HIV treatments demonstrate clinical promise but face coverage and implementation barriers.

Critical role of mental health services in HIV treatment and epidemic control.

Potential harms of state PDABs on HIV treatment access and ending the epidemic.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

OIG report: 27% of Medicaid HIV enrollees lack evidence of critical services; state disparities exposed.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Employers can advance health equity through inclusive benefits design and quality provider networks.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

Explores technology innovations in HIV care including mobile apps and drone pharmacy delivery.